Stockscreener 앱 받기
60.66
0.60%
0.36
시장 영업 전:
60.51
-0.15
-0.25%
전일 마감가:
$60.30
열려 있는:
$60.62
하루 거래량:
9.60M
Relative Volume:
0.68
시가총액:
$123.53B
수익:
$48.19B
순이익/손실:
$7.06B
주가수익비율:
17.54
EPS:
3.4587
순현금흐름:
$12.85B
1주 성능:
-0.13%
1개월 성능:
+11.88%
6개월 성능:
+25.69%
1년 성능:
+8.73%
1일 변동 폭
$59.65
$60.93
1주일 범위
$59.23
$61.30
52주 변동 폭
$42.52
$63.33
브리스톨 마이어스 스퀴브 Stock (BMY) Company Profile
명칭
Bristol Myers Squibb Co
전화
(609) 252-4621
주소
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
60.66 | 122.80B | 48.19B | 7.06B | 12.85B | 3.4587 |
|
LLY
Lilly Eli Co
|
1,009.52 | 965.26B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
242.49 | 595.03B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
224.81 | 396.51B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
204.20 | 323.42B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
162.67 | 312.78B | 54.72B | 14.02B | 15.32B | 7.1855 |
브리스톨 마이어스 스퀴브 Stock (BMY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Barclays | Overweight |
| 2026-01-07 | 업그레이드 | UBS | Neutral → Buy |
| 2025-12-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-12-12 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Perform |
| 2025-08-05 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 개시 | Piper Sandler | Overweight |
| 2024-12-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-13 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-07-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2024-03-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2024-02-06 | 다운그레이드 | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-11-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2023-10-27 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Reduce |
| 2023-07-10 | 개시 | SVB Securities | Market Perform |
| 2023-06-28 | 개시 | Daiwa Securities | Outperform |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-01-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 개시 | Credit Suisse | Neutral |
| 2022-10-10 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-09-14 | 다운그레이드 | Berenberg | Buy → Hold |
| 2022-06-03 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Underweight |
| 2021-12-17 | 개시 | Goldman | Buy |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-01 | 다운그레이드 | Argus | Buy → Hold |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-04-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | 업그레이드 | Truist | Hold → Buy |
| 2020-11-16 | 업그레이드 | Societe Generale | Hold → Buy |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-11-06 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2020-10-19 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-09-29 | 개시 | Berenberg | Buy |
| 2020-07-28 | 개시 | Raymond James | Outperform |
| 2020-04-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-06 | 재개 | Citigroup | Buy |
| 2019-12-13 | 업그레이드 | Argus | Hold → Buy |
| 2019-11-22 | 재개 | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 재개 | BofA/Merrill | Buy |
| 2019-08-14 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 개시 | Goldman | Buy |
| 2019-05-20 | 다운그레이드 | Argus | Buy → Hold |
| 2019-05-03 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 재개 | JP Morgan | Overweight |
| 2019-01-15 | 업그레이드 | Societe Generale | Sell → Buy |
| 2018-10-22 | 다운그레이드 | Citigroup | Buy → Neutral |
모두보기
브리스톨 마이어스 스퀴브 주식(BMY)의 최신 뉴스
Down 25%, Should You Buy the Dip on Bristol Myers Squibb? - The Motley Fool
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026? - The Globe and Mail
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus - Finviz
This Pfizer Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Friday - Benzinga
Barclays initiates Bristol-Myers Squibb stock coverage at overweight - Investing.com
ICICI Prudential Asset Management Co Ltd Grows Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Stem Cell and Regenerative Therapy Markets, 2022-2025 & - GlobeNewswire
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading CompaniesGilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More - Yahoo Finance
Barclays initiates Bristol-Myers Squibb stock coverage at overweight By Investing.com - Investing.com UK
Texas sues Sanofi for allegedly 'bribing' providers to boost drug prescriptions - Reuters
What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)? - Finviz
Starton Therapeutics Announces Dosing of First Patient in Phase 2a Study Evaluating STAR-LLD for the Treatment of Multiple Myeloma - GlobeNewswire Inc.
Bristol Myers Squibb (NYSE:BMY) Delivers Stability While S&P 500 Stays Volatile - Kalkine Media
FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma - Finviz
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development - Yahoo Finance
Bristol-Myers Squibb Co (NYSE:BMY) Offers a High Yield and Durable Dividend for Income Investors - ChartMill
We Like Bristol-Myers Squibb's (NYSE:BMY) Earnings For More Than Just Statutory Profit - simplywall.st
FDA accepts BMS protein degrader for review; Disc rare disease drug rejected - Yahoo Finance
Bristol Myers Squibb Company $BMY Shares Sold by Public Sector Pension Investment Board - MarketBeat
Juvenile Idiopathic Arthritis Market is Expected to Expand at a Healthy Growth Rate of 5.6% During the Forecast Period (2026-2036) | DelveInsight – Company AnnouncementFT.com - Financial Times
Iberdomide FDA Milestone Puts Fresh Focus On Bristol Myers Squibb Hematology - Yahoo Finance
U.S. FDA accepts Bristol Myers Squibb's NDA for iberdomide in multiple myeloma - marketscreener.com
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026? - TradingView
Bristol Myers Squibb gains FDA nod for multiple myeloma drug - Traders Union
FDA accepts Bristol Myers Squibb’s new drug application for iberdomide - Investing.com
Vanguard Group Inc. Has $8.84 Billion Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
FDA accepts Bristol Myers Squibb’s new drug application for iberdomide By Investing.com - Investing.com Canada
Bristol-Myers Squibb's Marketing Application for Cancer Therapy Accepted for Review by FDA - marketscreener.com
U.S. Food and Drug Administration accepts Bristol Myers Squibb's new drug application for iberdomide - marketscreener.com
Skandinaviska Enskilda Banken AB publ Has $167.77 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Colrain Capital LLC Has $8.03 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead? - Finviz
Bristol Myers Squibb Company $BMY Shares Acquired by M&G PLC - MarketBeat
Bristol Myers Squibb Company $BMY Shares Purchased by State of New Jersey Common Pension Fund D - MarketBeat
PNC Financial Services Group Inc. Sells 480,848 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Shell Asset Management Co. Has $1.52 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb (BMY) Stock Analysis: Is Its 4.15% Dividend Yield Enough for Investors? - DirectorsTalk Interviews
Short Interest in Bristol Myers Squibb Company (NYSE:BMY) Drops By 19.1% - MarketBeat
Berkshire Asset Management LLC PA Trims Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Acquired by Aberdeen Group plc - MarketBeat
Bristol-Myers Squibb Co (BMY) Stock Price, Trades & News - GuruFocus
Bristol Myers (BMY) Receives FDA Orphan Drug Status for Follicul - GuruFocus
Bristol-Myers Squibb Earnings Strength And Pipeline Shape Future Valuation - simplywall.st
Here's What Analysts Are Saying About Bristol-Myers Squibb Company (BMY) - Finviz
Here’s What Analysts Are Saying About Bristol-Myers Squibb Company (BMY) - Insider Monkey
Bristol Myers Squibb signs to Life Science Cares National Campaign to advance health equity and fight food insecurity - ROI-NJ
Caprock Group LLC Invests $2.99 Million in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Stock Holdings Lessened by Cibc World Market Inc. - MarketBeat
What Does the Market Think About Bristol-Myers Squibb Co? - Benzinga
LSV Asset Management Purchases 138,119 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb Company $BMY Shares Sold by Rhumbline Advisers - MarketBeat
브리스톨 마이어스 스퀴브 (BMY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
0.19%
자본화:
|
볼륨(24시간):